Recent Updates
Recently added Catalysts
SKYE Negative Sentiment Score: 20/100

Skye Bioscience, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – SKYE

Key Takeaway: Skye Bioscience, Inc. is embroiled in a class action securities lawsuit initiated by Levi & Korsinsky, LLP, affecting investors who suffered losses between November 4, 2024, and October 3, 2025. The lawsuit alleges that the company misrepresented the effectiveness and potential of its lead product candidate, nimacimab, resulting in misleading public statements. Investors are being encouraged to contact the law firm for more information, with a deadline of January 16, 2026, for those wishing to be appointed as lead plaintiff. There are no costs for class members to participate in the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • Skye Bioscience is facing a class action lawsuit for alleged securities fraud.
  • The company’s lead product candidate, nimacimab, may have been less effective than claimed.
  • Public statements made by the company were reportedly materially false and misleading.

Full Press Release Details

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Skye Bioscience, Inc. investors who were adversely affected by alleged securities fraud between November 4, 2024 and October 3, 2025. Follow the link below to get more information and be contacted by a member of our team:
SKYE investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i)The Company’s lead product candidate, nimacimab, was less effective than defendants had led investors to believe; (ii) accordingly, nimacimab’s clinical, regulatory, and commercial prospects were overstated; and (iii) as a result, defendants’ public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Skye Bioscience, Inc. during the relevant time frame, you have until January 16, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the class action lawsuit about Skye Bioscience?

The lawsuit aims to recover losses from investors affected by alleged securities fraud.

What is the time frame for the alleged fraud?

The fraud claims relate to events between November 4, 2024, and October 3, 2025.

What are the main allegations against Skye Bioscience?

The company misrepresented the effectiveness of its product candidate, nimacimab.

How can I participate in the lawsuit?

Investors can request to be lead plaintiff until January 16, 2026, at no cost.

Who can I contact for more information?

You can email Joseph E. Levi or call him at (212) 363-7500.

Last updated: Dec 12, 2025